Skip to main content

Advertisement

SpringerLink
Log in

Blockade of the Activation of T Cells Around β-Cell by the Targeted CTLA-4 Ig at the Surface of β-Cell

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Diabetes mellitus affects 347 million people worldwide, and over 80 % of diabetes deaths occur in low- and middle-income countries. Type 1 diabetes (T1D) is characterized by the attacks of the body’s own immune system on the pancreatic β-cells. In this work, we present a new CTLA-4 Ig targeting at the surface of β-cell and prepare it from Escherichia coli aiming at clearing activated T cells around β-cells and avoiding all-round decline in systematic immunity. This fusion protein is composed of CTLA-4-Ig part and β-cell-targeting part, with properties of the therapeutic effect of CTLA-4-Ig and selective binding to β-cells. In preliminary biological activity assay, our results verified the feasibility of β-cell-targeting strategy and its activity of CTLA-4-Ig part. The fusion protein recognizes and binds specifically to CD80+ and CD86+ cells as well as β-cell, but not to control cells, displaying the potential to be used as a feasible and effective treatment of T1D with lessened side effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bengtson, L. G., Kucharska-Newton, A., Wruck, L. M., et al. (2014). Comparable ascertainment of newly-diagnosed atrial fibrillation using active cohort follow-up versus surveillance of centers for medicare and medicaid services in the atherosclerosis risk in communities study. PLoS One, 9, e94321.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Atkinson, M. A., & Eisenbarth, G. S. (2001). Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet, 358, 221–229.

    Article  CAS  PubMed  Google Scholar 

  3. van Belle, T. L., Coppieters, K. T., & von Herrath, M. G. (2011). Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiological Reviews, 91, 79–118.

    Article  PubMed  Google Scholar 

  4. Jin, H., Li, C., Li, D., et al. (2013). Construction and characterization of a CTLA-4-targeted scFv-melittin fusion protein as a potential immunosuppressive agent for organ transplant. Cell Biochemistry and Biophysics, 67, 1067–1074.

    Article  CAS  PubMed  Google Scholar 

  5. Jain, N., Nguyen, H., Chambers, C., & Kang, J. (2010). Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 107, 1524–1528.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002). CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nature Immunology, 3, 611–618.

    Article  CAS  PubMed  Google Scholar 

  7. Schneider, H., Downey, J., Smith, A., et al. (2006). Reversal of the TCR stop signal by CTLA-4. Science, 313, 1972–1975.

    Article  CAS  PubMed  Google Scholar 

  8. Boni, A., Cogdill, A. P., Dang, P., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70, 5213–5219.

    Article  CAS  PubMed  Google Scholar 

  9. Guo, J., Si, L., Kong, Y., et al. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. Journal of Clinical Oncology, 29, 2904–2909.

    Article  CAS  PubMed  Google Scholar 

  10. Salama, A. K., & Hodi, F. S. (2011). Cytotoxic T-lymphocyte-associated antigen-4. Clinical Cancer Research, 17, 4622–4628.

    Article  CAS  PubMed  Google Scholar 

  11. Ueberberg, S., Deutschbein, T., Klein, H. H., et al. (2011). Protection from diabetes development by single-chain antibody-mediated delivery of a NF-kappaB inhibitor specifically to beta-cells in vivo. American Journal of Physiology: Endocrinology and Metabolism, 301, E83–E90.

    CAS  PubMed  Google Scholar 

  12. Ueberberg, S., Meier, J. J., Waengler, C., et al. (2009). Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo. Diabetes, 58, 2324–2334.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Ueberberg, S., Ziegler, D., Schechinger, W., et al. (2010). In vitro phage display in a rat beta cell line: A simple approach for the generation of a single-chain antibody targeting a novel beta cell-specific epitope. Diabetologia, 53, 1384–1394.

    Article  CAS  PubMed  Google Scholar 

  14. Yang, W., Lu, J., Weng, J., et al. (2010). Prevalence of diabetes among men and women in China. New England Journal of Medicine, 362, 1090–1101.

    Article  CAS  PubMed  Google Scholar 

  15. Tian, J., Atkinson, M. A., Clare-Salzler, M., et al. (1996). Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. Journal of Experimental Medicine, 183, 1561–1567.

    Article  CAS  PubMed  Google Scholar 

  16. Hagopian, W., Ferry, R. J., Jr, Sherry, N., et al. (2013). Teplizumab preserves C-peptide in recent-onset type 1 diabetes: Two-year results from the randomized, placebo-controlled Protege trial. Diabetes, 62, 3901–3908.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Herold, K. C., Gitelman, S. E., Willi, S. M., et al. (2013). Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: A randomised controlled trial. Diabetologia, 56, 391–400.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Orban, T., Bundy, B., Becker, D. J., et al. (2011). Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial. Lancet, 378, 412–419.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Montes, V. N., & Hirsch, I. B. (2012). Treatment of LADA with etanercept. Diabetes Care, 35, e36.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Moran, A., Bundy, B., Becker, D. J., et al. (2013). Interleukin-1 antagonism in type 1 diabetes of recent onset: Two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, 381, 1905–1915.

    Article  CAS  PubMed  Google Scholar 

  21. Pescovitz, M. D., Greenbaum, C. J., Bundy, B., et al. (2014). B-lymphocyte depletion with rituximab and beta-cell function: Two-year results. Diabetes Care, 37, 453–459.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Deng, C., Xiang, Y. F., & Zhou, Z. G. (2013). Biologic therapies in type 1 diabetes: How far are they from us? Chinese Medical Journal (English), 126, 4003–4005.

    Google Scholar 

  23. Wong, F. S., & Wen, L. (2013). Therapy: Immunotherapy for T1DM: Targeting innate immunity. Nature Reviews Endocrinology, 9, 384–385.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Mayer, E., Holzl, M., Ahmadi, S., et al. (2013). CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. International Immunopharmacology, 15, 638–645.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This project is supported by China Postdoctoral Science Foundation 20080441294.

Author information

Authors and Affiliations

  1. Endocrinology Department, Jinan Military General Hospital, Jinan, 250031, China

    Wei Qu, Lin Li, Chendong Han, Meihua Li, Jing Wang, Chaohui Yin & Zhaoshun Jiang

  2. Department of Cadre Ward No. 3, Jinan Military General Hospital, Jinan, 250031, China

    Jing Zhang

Authors
  1. Wei Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chendong Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meihua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chaohui Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhaoshun Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhaoshun Jiang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qu, W., Li, L., Han, C. et al. Blockade of the Activation of T Cells Around β-Cell by the Targeted CTLA-4 Ig at the Surface of β-Cell. Cell Biochem Biophys 71, 913–918 (2015). https://doi.org/10.1007/s12013-014-0282-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0282-0

Keywords

Search

Navigation